Ketabon
  • About us
  • Medical Need
  • Our Aim
  • News
  • Investors
  • Contact
Treating Treatment Resistant Depression

Legal Notice
Pursuant to § 5 TMG

Legal Notice
Pursuant to §5 TMG


Ketabon GmbH
Wilhelm-Wagenfeld-Straße 20
D-80807 Munich

Phone: +49 (0)89 - 360 90 200
Email: info[at]ketabon[dot]health

Handelsregister: HRB 237179
Registration court: Amtsgericht München

Represented by the managing directors: Dr. Markus Zimmer, Dr. Maximilan Doebler,

Sales tax identification number according to § 27 a of the Sales Tax Law: DE316656328

We are not willing or obliged to participate in dispute resolution proceedings before a consumer arbitration board.

Liability for Contents

As service providers, we are liable for own contents of these websites according to Sec. 7, paragraph 1 German Telemedia Act (TMG). However, according to Sec. 8 to 10 German Telemedia Act (TMG), service providers are not obligated to permanently monitor submitted or stored information or to search for evidences that indicate illegal activities.

Legal obligations to removing information or to blocking the use of information remain unchallenged. In this case, liability is only possible at the time of knowledge about a specific violation of law. Illegal contents will be removed immediately at the time we get knowledge of them.

The information contained in this website is for general information purposes only. The information contained on this webpage does not constitute an offer to the public or an offer for sale or solicitation to purchase or subscribe for any securities of Ketabon GmbH and it should not be relied on in connection with a decision to purchase or subscribe for any such securities.

The information has been compiled to the best of our knowledge and belief. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

Statements made on this webpage may include forward-looking statements that necessarily involve risks and uncertainties. Forward-looking statements may generally be identified by the use of terminology such as “may”, “will”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, or similar phrases. Other than statements of historical facts, all statements, including, among others, statements regarding the future financial position of the company, business strategy, projected levels of growth in its market (arising from either internal or external analyses), projected costs, estimates of capital expenditures as well as plans and objectives of management for future operation, are forward-looking statements. The actual future performance of the company could differ materially from these forward-looking statements. Important factors that could cause actual results to differ materially from these expectations include known and unknown risks. Undue reliance should not be placed on these forward-looking statements.

Liability for Links

Our offer includes links to external third party websites. We have no influence on the contents of those websites, therefore we cannot guarantee for those contents. Providers or administrators of linked websites are always responsible for their own contents.

The linked websites had been checked for possible violations of law at the time of the establishment of the link. Illegal contents were not detected at the time of the linking. A permanent monitoring of the contents of linked websites cannot be imposed without reasonable indications that there has been a violation of law. Illegal links will be removed immediately at the time we get knowledge of them.

Copyright

Contents and compilations published on these websites by the providers are subject to German copyright laws. Reproduction, editing, distribution as well as the use of any kind outside the scope of the copyright law require a written permission of the author or originator. Downloads and copies of these websites are permitted for private use only.

The commercial use of our contents without permission of the originator is prohibited.

Copyright laws of third parties are respected as long as the contents on these websites do not originate from the provider. Contributions of third parties on this site are indicated as such. However, if you notice any violations of copyright law, please inform us. Such contents will be removed immediately.

Design, realization and support

Ketabon - Brain Health

Wilhelm-Wagenfeld-Straße 20
D-80807 München
+49 (0)89 - 360 90 200
info@ketabon.health

Legal notice

Disclaimer

Privacy Policy

Copyright 2023 © Ketabon GmbH

Dr. Markus Zimmer
LinkedIn

Dr. Markus Zimmer, Co-CEO

Dr. Markus Zimmer is Co-CEO of Ketabon, together with Dr. Maximilian Döbler.

Besides his responsibilities at Ketabon, Markus is also Member of the Board of Directors at Develco Pharma and Helmadis – both founding partners of Ketabon. Prior to this, Markus served as Member of the Board of Directors and COO at Algobate and founded as well as headed YES Pharma Services, today known as PharmaLex.

Markus holds a PhD in Pharmaceutical Sciences.

Dr. Maximilian Döbler
LinkedIn

Dr. Maximilian Döbler, Co-CEO

Together with Dr. Markus Zimmer, Dr. Maximilian Döbler as Co-CEO is responsible for all business and corporate development activities at Ketabon. He focuses on the company’s partnership agreements and strategy development, including potential deals and cooperations. Furthermore, Maximilian coordinates the company’s marketing and communication activities.

Besides his responsibilities at Ketabon, Maximilian is Chief Business Officer at HMNC Brain Health – one of Ketabon’s founding partners. Prior to his time at HMNC Brain Health and Ketabon, he worked in various roles for KPMG and the Maschmeyer Group.

Maximilian holds a Doctor of Laws from the University of Salzburg.

Dr. Hans Eriksson
LinkedIn

Dr. Hans Eriksson, CMO

Dr. Hans Eriksson has more than 20 years of experience in clinical development of therapeutics for psychiatric indications. As Chief Medical Officer at Ketabon he leads the clinical programs, ensuring that the strategies are aligned with the promises of the compounds in development.

Besides his responsibilities at Ketabon, Hans is Chief Medical Officer at HMNC Brain Health – one of Ketabon’s founding partners. Prior to this, Hans has held several senior clinical development roles in the pharmaceutical industry, in Sweden, Denmark, USA, and the UK. He also served as Consultant Psychiatrist and Assisting Head of the Psychiatric Clinic at Lund University Hospital.

Hans holds a MD and PhD in Cell and Molecular Biology from Lund University as well as an Executive MBA from Stockholm School of Economics.